COMMUNIQUÉS West-GlobeNewswire

NEXGEL Reports First Quarter 2025 Financial Results
13/05/2025
First quarter 2025 revenue totaled $2.81 million, an increase of 121%, as compared to $1.27 million for the same period the prior year Gross Profit for the quarter was 42.4%, compared to 12.6% in Q1 2024 and 37.2% in Q4 [...]
Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update
13/05/2025
Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) Nearly 50 Sites Activated Across U.S. with Strong Enthusiasm from Investigators [...]
Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results
13/05/2025
– Company reports $3.4 million in YCANTH revenue, reflective of increasing demand, following the dispensing of more than 10,000 applicator units in the quarter, the most in company history and a 16.7% growth over Q4’24 [...]
Fractyl Health Announces First Quarter 2025 Financial Results and Business Updates
13/05/2025
REVEAL-1 Cohort 3-month open-label data update expected in June 2025; early clinical signals reinforce Revita’s potential to maintain weight loss after GLP-1 discontinuation in the real world REMAIN-1 Midpoint Cohort [...]
Hyperfine, Inc. Reports First Quarter 2025 Financial Results
13/05/2025
GUILFORD, Conn., May 13, 2025 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic [...]
Vaxart Provides Business Update and Reports First Quarter 2025 Financial Results
13/05/2025
Actively screening for the 10,000 participant portion of COVID-19 Phase 2b trial; Dosing expected to begin in second quarter of 2025 Completed enrollment of Phase 1 clinical trial evaluating Company’s second-generation [...]
MannKind to Present at Upcoming Investor Conferences
13/05/2025
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of innovative inhaled therapeutic products [...]
Elicio Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Updates
13/05/2025
Interim analysis focused on disease-free survival (“DFS”) in randomized Phase 2 AMPLIFY-7P clinical trial expected in Q3 2025 Company has alignment with U.S. Food and Drug Administration (“FDA”) on key design elements [...]
Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update
13/05/2025
sunRIZE enrollment on track including U.S. sites and expected to be completed in May 2025; topline data anticipated in December 2025 U.S. Food and Drug Administration (FDA) grants Breakthrough Therapy Designation to [...]
Erasca Reports First Quarter 2025 Business Updates and Financial Results
13/05/2025
Early entry of RAS-targeting franchise into clinic enabled by strong execution Initial Phase 1 monotherapy data for pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 expected in 2026 Robust balance sheet [...]
SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update
13/05/2025
– Announced Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 (tambiciclib) in Relapsed/Refractory (r/r) Acute Myeloid Leukemia (AML) Demonstrating 8.9 mOS in AML-MRC and 8.8 mOS in All r/r [...]
Pharvaris Reports First Quarter 2025 Financial Results and Provides Business Update
13/05/2025
Enrollment underway in CHAPTER-3, a pivotal Phase 3 study of deucrictibant for prophylaxis of HAE attacks; topline data expected in 2H2026 Attack dataset continues to accumulate in RAPIDe-3, a pivotal Phase 3 study of [...]
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025
13/05/2025
Presenting new clinical data from Phase 1/2 multi-center clinical trial of LYL314, a next-generation dual‑targeting CD19/CD20 CAR T-cell product candidate for the treatment of relapsed and/or refractory large B‑cell [...]
Artiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting
13/05/2025
64% (9/14) complete response rate with AlloNK + rituximab in heavily pretreated patients that were naïve to prior CAR-T cell therapy, in line with approved auto-CAR-T therapies in aggressive B-NHL Median duration of [...]
Seer Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Outlook
13/05/2025
Revenue grew 37%, driven by increased product sales and service revenue REDWOOD CITY, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new [...]
Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update
13/05/2025
- Announced preclinical data demonstrating the bioequivalence of RT-114, a bispecific GLP-1/GLP-2 receptor agonist (PG-102), delivered orally via the RaniPill® capsule, to subcutaneous administration of PG-102 - - Phase [...]
CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights
13/05/2025
Phase 1 clinical trial of CMP-CPS-001 in Urea Cycle Disorders (UCDs) ongoing, with dosing completed in multiple ascending dose (MAD) cohort 3; safety, pharmacokinetic, and pharmacodynamic data expected Q4 2025 CTA [...]
Evoke Pharma Reports First Quarter 2025 Financial Results and Provides Business Update
13/05/2025
Q1 2025 Net Product Sales Increased 77% Year-over-Year to $3.1 Million Sustained Momentum Driven by Growing Prescriber Adoption and Repeat Patient Use SOLANA BEACH, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma [...]
Avadel Pharmaceuticals Expands Leadership Team with Appointment of Susan Rodriguez as Chief Operating Officer
13/05/2025
DUBLIN, May 13, 2025 (GLOBE NEWSWIRE) -- DUBLIN, May 13, 2025 – Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the [...]

Pages